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Abstract
Background: Nurr1, a member of the orphan receptor family, plays an important role in several types of cancer. Our
previous work demonstrated that increased expression of Nurr1 plays a significant role in the initiation and progression
of prostate cancer (PCa), though the mechanisms for regulation of Nurr1 expression remain unknown. In this study, we
investigated the hypothesis that Nemo-like kinase (NLK) is a key regulator of Nurr1 expression in PCa.
Methods: Immunohistochemistry and Western blot analysis were used to evaluate levels of NLK and Nurr1 in prostatic
tissues and cell lines. The effects of overexpression or knockdown of Nurr1 were evaluated in PCa cells through use of
PCR, Western blots and promoter reporter assays. The role of Nurr1 promoter cis element was studied by creation of
two mutant Nurr1 promoter luciferase constructs, one with a mutated NF-κB binding site and one with a mutated
CREB binding site. In addition, three specific inhibitors were used to investigate the roles of these proteins in
transcriptional activation of Nurr1, including BAY 11–7082 (NF-κB inhibitor), KG-501 (CREB inhibitor) and ICG-001 (CREB
binding protein, CBP, inhibitor). The function of CBP in NLK-mediated regulation of Nurr1 expression was investigated
using immunofluorescence, co-immunoprecipitation (Co-IP) and chromatin immunoprecipitation assays (ChIPs).
Results: NLK expression was inversely correlated with Nurr1 expression in prostate cancer tissues and cell lines.
Overexpression of NLK suppressed Nurr1 promoter activity, leading to downregulation of Nurr1 expression. In contrast,
knockdown of NLK demonstrated opposite results, leading to upregulation of Nurr1. When compared with the
wild-type Nurr1 promoter, mutation of NF-κB- and CREB-binding sites of the Nurr1 promoter region significantly
reduced the upregulation of Nurr1 induced by knockdown of NLK in LNCaP cells; treatment with inhibitors of CREB,
CBP and NF-κB led to similar results. We also found that NLK directly interacts with CBP, that knockdown of NLK
significantly increases the recruitment of CBP to both NF-κB- and CREB-binding sites, and that regulation of NLK on
Nurr1 expression is abrogated by knockdown of CBP.
Conclusions: Our results suggest that NLK inhibits transcriptional activation of Nurr1 gene by impeding CBP’s role as a
co-activator of NF-κB and CREB in prostate cancer.
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Background
In both Europe and the United States, prostate cancer
(PCa) is a common malignancy and the leading cause of
cancer-associated death among men [1, 2]. Although the
incidence of PCa is still lower in Asian than in Western
countries, it has been rapidly increasing in recent years
due to a more Westernized lifestyle [3]. For patients
with localized or regional disease, the prognosis is good;
however, median survival in patients with clinically
detectable metastasis is only 12–15 months [4–6].
Unfortunately, the exact mechanisms involved in PCa
initiation and progression are still unclear, highlighting the
need to identify novel biomarkers and clinically-applicable
molecular targets for the diagnosis, monitoring and treat-
ment of this disease [7].
The nuclear receptor Nurr1 is a transcription factor
belonging to the superfamily of nuclear steroid hormone
receptors [8]. It is involved in a wide variety of biological
processes, including regulation of proliferation, apop-
tosis, migration and differentiation in a cell type-specific
manner [9–13]. In recent years, the oncogenic functions
of Nurr1 have been reported in several types of cancer
[11, 14, 15]. In fact, our previous work suggests that up-
regulation of Nurr1 provides a selective advantage in the
initiation and progression of PCa, and that knockdown
of Nurr1 inhibits proliferation, migration and invasion of
PCa cells and also induces their apoptosis [16]. Taken
together, these results suggest that Nurr1 may be a novel
marker of PCa, though the mechanisms behind Nurr1
upregulation remain unknown.
Nemo-like kinase (NLK), an evolutionarily conserved
serine/threonine kinase, is a member of the mitogen-
activated protein kinase (MAPKs) [17, 18]. Recent stud-
ies show that NLK expression is altered in various types
of human cancer, acting as either an oncogene or tumor
suppressor depending upon tumor type [19–21]. In PCa,
NLK appears to act as a tumor suppressor, with mRNA
expression decreasing concomitant with the development
of cancer [22]. NLK may perform this tumor suppressive
function in PCa through its suppression of the NF-κB-
and CREB-mediated transcription [23–25], and interest-
ingly, the promoter region of the human Nurr1 gene con-
tains both NF-κB- and CREB-binding sites [26]. This data
led us to hypothesize that NLK regulates Nurr1 expression
in PCa. Here we report for the first time that Nurr1 ex-
pression is inversely correlated with NLK in PCa tissues
and cell lines, and that transcriptional activation of the
Nurr1 gene is repressed by NLK in PCa cells.
Methods
Tissue samples
Human PCa specimens were derived from patients
undergoing radical prostatectomy, and the benign pros-
tate tissue samples were derived from benign prostatic
hyperplasia (BPH) patients. Specimens were formalin-
fixed and paraffin-embedded for histopathologic diagno-
sis and immunohistochemical analysis. Eight paired fresh
specimens were frozen in liquid nitrogen immediately
following surgical removal and maintained at −80 °C
until use (Western blots). Patient clinical features, in-
cluding age, Gleason score and tumor node metastasis
(TNM) staging, are shown in Table 1. This study was ap-
proved by the ethics committee of Jinzhou People’s Hos-
pital. Written informed consent for anonymized use of
tissue specimens was obtained from all patients.
Immunohistochemistry
Human prostate tissues were processed for immuno-
staining with rabbit anti-Nurr1 polyclonal antibody
(2 μg/ml, Santa Cruz, CA, USA) and rabbit anti-NLK
polyclonal antibody (4 μg/ml, Abcam, Cambridge, MA,
USA) as described previously [16]. Stained tissue sec-
tions were scored independently by two pathologists
Table 1 Correlation between NLK expression and
clinicopathological parameters of PCa patients
No NLK protein expression (%) p
High Low
Group
BPH 50 31 (62.0) 19 (38.0) .003
PCa 118 44 (37.3) 74 (62.7)
Age (year)
<70 45 14 (31.1) 31 (68.9) .276
≥70 73 30 (41.1) 43 (58.9)
Gleason score
4–6 42 28 (66.7) 14 (33.3) <.001
7 20 7 (35.0) 13 (65.0)
8–10 56 9 (16.1) 47 (83.9)
CS (TNM)
T stage
T1-T2 56 28 (50.0) 28 (50.0) .007
T3-T4 62 16 (25.8) 46 (74.2)
N stage
N0 90 39 (43.3) 51 (56.7) .015
N1 28 5 (17.9) 23 (82.1)
M stage
M0 94 39 (41.5) 55 (58.5) .065
M1 (bone) 24 5 (20.8) 19 (79.2)
Nurr1 expression
High 84 18 (21.4) 66 (78.6) <.001
Low 34 26 (76.5) 8 (23.5)
Statistical analyses were performed by the Pearson χ2 test, p < 0.05 was
considered significant
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blinded to the clinical parameters. The intensity of stain-
ing was evaluated subjectively on a scale of 0–3, where
0 = no staining, 1 = weak equivocal staining, 2 = un-
equivocal moderate staining and 3 = strong staining. The
extent of staining, defined as the percentage of positive
staining cells in relation to the whole field, was scored
on a scale of 0 to 4 as 0 (≤5 %), 1 (6 to 25 %), 2 (26 to
50 %), 3 (51 to 75 %) or 4 (>75 %). Values for staining in-
tensity and positive area were multiplied to give the final
score. For statistical analysis, final staining scores of < 4
and ≥ 4 were considered to be low and high expression
levels, respectively.
Cell culture
Three prostate cell lines (LNCaP, PC-3 and BPH-1) were
obtained from American Type Culture Collection (Rock-
ville, MD, USA). Cells were cultured in RPMI-1640
media (Invitrogen, Carlsbad, CA, USA) supplemented
with 100 IU/mL penicillin G sodium, 100 mg/mL
streptomycin sulfate and 10 % (v/v) fetal bovine serum
(Hyclone, Logan, UT, USA). Cultures were maintainedat
37 °C in a 5 % CO2 environment.
Small-interfering RNA knockdown
NLK expression in PCa cells was knocked down using
NLK-specific shRNA plasmid vectors. The shRNA-NLK
(target sequence: 5′-GAATATCCGCTAAGGATGC-3′),
shRNA-CBP (target sequence: 5′-AACAGTGGGAACCTT
GTTCCA-3′) and shRNA-control plasmids were obtained
from GenePharma (Shanghai, China). Cells were grown to
70 % confluency in 6-well plates and transfected with 2 μg
specific or nonspecific shRNA plasmid using Lipofectamine
LTX Plus (Invitrogen, Carlsbad, USA) according to the
manufacturer′s instructions. Cells were harvested 48 h after
transfection and used in further experiments.
Protein expression from plasmid vectors
The human NLK cDNA clone was obtained from Sino
Biological Inc (Beijing, China). The NLK coding sequence
was amplified by PCR using the following primers: 5′-
GAGCGGATAACAATTTCACACAGG-3′ (forward) and
5′-CGCCAGGGTTTTCCCAGTCACGAC-3′ (reverse).
The resultant PCR fragment was cloned into the
pcDNA3.1 expression vector using the HindIII and XbaI
restriction sites. Proper insertion of the clone was con-
firmed by DNA sequencing, and the plasmid was prepared
for transfection using the Genopure Plasmid Maxi Kit
(Roche, Basel, Switzerland). Transfection was performed
using the Lipofectamine LTX Plus (Invitrogen, Carlsbad,
USA) according to the manufacturer’s protocol. Cells were
grown to 70 % confluency in 6-well plates and transfected
with pcDNA3.1-NLK vector (1 μg) or pcDNA3.1 vector
(1 μg). Cells were harvested and used in further experi-
ments 48 h following transfection.
Western blotting
Western blots were performed in triplicate as previously
described [16]. The following antibodies were used for
Western blot: rabbit anti-Nurr1 polyclonal antibody
(1:500, Santa Cruz, CA, USA), rabbit anti-NLK poly-
clonal antibody (1:250, Abcam, Cambridge, MA, USA),
rabbit anti-NF-κB p65 polyclonal antibody (1:200, Santa
Cruz, CA, USA), mouse anti-IκBα monoclonal antibody
(1:1000, Abcam, Cambridge, MA, USA), mouse anti-CREB
monoclonal antibody (1:500, Santa Cruz, CA, USA), rabbit
anti-phospho-CREB polyclonal antibody (Ser133; 1:100,
Santa Cruz, CA, USA), mouse anti-β-tubulin monoclonal
antibody (1:500, Santa Cruz, CA, USA), rabbit anti-
Histone H3 polyclonal antibody (1:250, Santa Cruz, CA,
USA), mouse anti-β-actin monoclonal antibody (1:1000,
Santa Cruz, CA, USA) and mouse anti-CBP monoclonal
antibody (1:500, Abcam, Cambridge, MA, USA). Band
density was measured with Image J software and normal-
ized against internal control levels.
Real-time quantitative RT-PCR
Total RNA was isolated from cultured cells 48 h post-
transfection using TRIzol reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions.
Reverse transcription was carried out using the iScriptTM
cDNA synthesis kit (Bio-Rad Laboratories Inc., Hercules,
CA, USA). Fluorescent real-time PCR was carried out in
the Bio-Rad iCycler System (Bio-Rad) with a final volume
of 10 μl for each reaction. The following primers were
used: 5′-TCCAACGAGGGGCTGTGCG-3′ (forward)
and 5′-CACTGTGCGCTTAAAGAAGC-3′ (reverse) for
human Nurr1; and 5′-GAAGGTGAAGGTCGGAGTC-3′
(forward) and 5′-GAAGATGGTGATGGGATTTC-3′
(reverse) for human GAPDH (internal control). The PCR
program was as follows: initial cycle of 95 °C for 3 min,
followed by 40 cycles of 95 °C for 15 s, 59.5 °C for 60 s.
PCR products were detected using the fluorescent dye
SYBR Green I (BioTeke, Beijing, China), and threshold
cycle (Ct) values were generated after every cycle in the
run. Fluorescent readings from real-time PCR were quan-
titatively analyzed by finding the difference between Ct
values (delta Ct) of the target and its internal con-
trol, with target gene expression determined using
the formula 2-delta Ct [25]. This experiment was repeated
three times.
Luciferase reporter gene assay
A fragment of the human Nurr1 promoter region
was amplified by PCR using specific primers (forward
5′-AGTTGGTGGGCACAGAGGAGTATC-3′ and re-
verse 5′-TCACGGAGGGAGGGAGCAG-3′), then
cloned into the pGL3-Basic luciferase reporter vector
(Promega, Madison, USA) and sequenced to confirm
generation of the pGL3-Nurr1-promoter plasmid. A
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site-directed mutagenesis kit (Stratagene, La Jolla,
CA) was used to mutate the core GA sequence of
the NF-κB-binding site or the core AC sequence of
the CREB-binding site in luciferase constructs. Cells
were transfected with wild-type (wt) or mutant (mt)
Nurr1 promoter luciferase constructs (1 μg) and with
the effector plasmids pcDNA3.1 (1 μg), pcDNA3.1-
NLK (1 μg), shRNA-control (2 μg) or shRNA-NLK
(2 μg). The TK renilla luciferase plasmid (2 ng) was
transfected under the same conditions to enable
normalization of transfection efficiencies. Twelve hours
after transfecting with WT-Nurr1 promoter constructs,
cells were treated with DMSO (control, 1 % DMSO
in PBS), BAY 11–7082 (NF-κB inhibitor, 10 μM), KG-
501 (CREB inhibitor, 25 μM) or ICG-001 (CBP inhibi-
tor, 25 μM). Firefly and renilla luciferase activities
were measured 48 h after transfection in cell extracts
using the Dual-Luciferase Reporter Assay System
(Promega, Madison, USA). This experiment was repeated
three times.
Immunofluorescence microscopy
LNCaP cells grown on coverslips were washed 3 times with
PBS, fixed in 4 % paraformaldehyde for 30 min at room
temperature and permeabilized with 0.2 % Triton X-100
solution in PBS for 10 min at room temperature. Next, the
samples were incubated in 5 % BSA solution in PBS for 1 h
at room temperature to saturate non-specific binding sites.
Incubation with the primary antibodies, diluted in 5 % BSA
solution in PBS, was performed overnight at 4 °C. Primary
antibodies were rabbit anti-NLK polyclonal antibody
(1:100, Abcam, Cambridge, MA, USA) and mouse anti-
CBP monoclonal antibody (1:200, Abcam, Cambridge,
MA, USA). The next day, cells were incubated for 1 h
at room temperature in secondary FITC-conjugated
anti-rabbit and Cy3-conjugated anti-mouse antibodies
(1:300, Sigma-Aldrich, St. Louis, MO, USA). Confocal
analysis was performed on a Leica TCS SP5 micro-
scope, with excitation wavelengths set to 488 and
543 nm for dual channel imaging.
Co-Immunoprecipitation (Co-IP)
Five hundred microgramme of protein lysates from
LNCaP cells were incubated with 2 μg of rabbit anti-
NLK antibody or mouse anti-CBP antibody overnight at
4 °C on an oscillation shaker. Next, 50 μl of suspensions
were generated by mixing samplesina 1:1 ratio with pro-
tein A-Sepharose beads and then incubated for 2 h at 4 °C
with gentle rotation. To ensure specificity of the detected
associations, control IPs with rabbit IgG or mouse IgG in
place of the primary antibodies were performed under the
same conditions. After extensive washing, precipitates
were subjected to Western blotting analyses for detection
of potential interacting proteins.
Chromatin immunoprecipitation assay (ChIP)
Chromatin immunoprecipitations were carried out 48 h
after transfection with shRNA-NLK using the MAGnify™
Chromatin Immunoprecipitation System (Invitrogen,
Carlsbad, USA) according to the manufacturer’s guide-
lines. Briefly, LNCaP cells (6 × 106) were fixed with for-
maldehyde and sonicated. Immunoprecipitation was
carried out with 5 μg of mouse anti-CBP antibody
(Abcam, Cambridge, MA, USA) or mouse IgG at 4 °C
overnight with rotation. The immunoprecipitates were
washed and eluted, and purified DNA was obtained.
Purified immunoprecipitated DNA and input DNA were
used as templates for subsequent real-time PCR. ChIP
primer sets were checked for linear amplification and
designed to amplify two separate regions of the human
Nurr1 promoter: NF-κB element forward (5′-TGGGACA
GGAAAAGGGAGTA-3′) and reverse (5′-ACAGATGTC
CCATGACACGA-3′), spanning nucleotides −633 to
−536; and CREB element forward (5′- AACCACCCA
AGCTGGCTAC-3′) and reverse (5′-TGGTATATTTCCG
ACCTGACG-3′), spanning nucleotides −252 to −163.
Statistical analysis
Results are expressed as mean ± SD and are representa-
tive of at least three separate experiments. The student’s
t-test was used to determine statistical differences in the
means of two columns. The Pearson χ2 test and Fisher’s
exact test were used to analyze the relationship between
the expression of NLK and the patient’s various clinico-
pathological parameters. The nonparametric Spearman’s
rank correlation coefficient was used to determine the
statistical dependence between the expression of NLK
and Nurr1. A p value < 0.05 was regarded as statistically
significant. All computations were performed using the
SPSS 13.0 software.
Results
NLK expression is inversely correlated with Nurr1
expression in PCa
To explore the clinical significance of NLK in the occur-
rence and progression of PCa and further characterize
the relationship between NLK and Nurr1, we examined
the levels of NLK and Nurr1 using immunohistochemi-
cal staining in 118 PCa and 50 benign prostate tissue
samples. Representative examples of staining are shown
in Fig. 1a (I-IX), which show that epithelial cells from
benign prostate gland samples have strong nuclear NLK
staining (Fig. 1a IV) and weak Nurr1 staining (Fig. 1a
VII), and also that low NLK levels (Fig. 1a VI) correlate
with high Nurr1 levels (Fig. 1a IX) in the same PCa
specimens (high-grade PCa). Correlation analysis dem-
onstrated a significant negative correlation between NLK
and Nurr1 expression levels in PCa tissue specimens
(Fig. 2). Furthermore, we investigated the abundance of
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NLK and Nurr1 in eight tumors relative to the adjacent
normal tissues (Fig. 1b) by Western blot. The results in-
dicate that compared with the non-tumorous adjacent
tissue, NLK expression was dramatically lower and
Nurr1 expression much higher in the tumor tissues. To
further characterize the relationship between NLK and
Nurr1, we investigated their abundance in a normal human
prostate epithelial cell line (BPH-1) and two human pros-
tate cancer cell lines (PC-3 and LNCaP) by Western blot
analysis. Different expression levels of NLK and Nurr1
were observed in all of the cells (Fig. 1c). As expected,
relative abundances of NLK and Nurr1 appeared to be in-
versely correlated in BPH-1, PC-3 and LNCaP cells. PC-3
cells displayed the lowest abundance of NLK and the high-
est expression of Nurr1 among the three cell lines.
Correlation of NLK expression with clinicopathological
features in PCa
The frequencies of NLK immunostaining in relation to
the different clinicopathological parameters and Nurr1
expression levels are shown in Table 1. For statistical
analysis of NLK and Nurr1 expression, the specimens were
Fig. 1 Expression of NLK and Nurr1 in human prostate cancer. a (I-IX): Paraffin-embedded tissue sections were stained with antibodies for NLK
and Nurr1 and then counterstained with hematoxylin (×400). I-III: Negative controls for benign prostate gland and PCa specimens; IV: High NLK
expression in benign prostate gland specimen; V: Medium NLK expression in low-grade PCa specimen; VI: Low NLK expression in high-grade PCa
specimen; VII: Low Nurr1 expression in benign prostate gland specimen; VIII: Medium Nurr1 expression in low-grade PCa specimen; IX: High Nurr1
expression in high-grade PCa specimen. b Western blotting was performed to study the protein levels of NLK and Nurr1 in eight representative
paired samples of PCa tissues (T) and non-tumorous adjacent tissues (N). c Western blot analysis of endogenous NLK and Nurr1 in BPH-1, PC-3
and LNCaP cells. Results are plotted as mean ± SD for three independent experiments. *p < 0.05, assessed by Student’s t-test
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divided into two groups (high expressers and low ex-
pressers), according to staining intensity and the percent-
ages of positive cells. The level of NLK protein was
significantly less in the 118 PCa tissue samples compared
to the 50 benign prostate tissue samples (p < 0.001). In our
PCa tissue specimens, the frequency of NLK low expres-
sion increased with progressive T classification (p = 0.007),
N classification (p = 0.015) and Gleason score (p < 0.001),
though no correlation was observed with other prognostic
factors such as age and M classification. As expected, NLK
expression was negatively correlated with Nurr1 expression
in all of the analyzed PCa tissue samples (p < 0.001).
NLK contributes to inhibition of Nurr1 expression in
human PCa cells
To elucidate the biological importance of NLK in the
regulation of Nurr1 gene expression, we used RNA
interference to knock down NLK expression in LNCaP
cells with a higher level of NLK expression. In contrast,
we used transient transfection to upregulate NLK expres-
sion in PC-3 cells with lower levels of NLK expression.
Levels of Nurr1 protein and mRNA were determined by
Western blot analysis and real-time PCR, respectively. As
shown in Fig. 3a, b, transfection of the shRNA-NLK vector
into LNCaP cells strongly reduced NLK protein levels,
whereas shRNA-control vector transfection had no effect
on NLK expression. In addition, levels of endogenous
Nurr1 mRNA and protein were significantly upregulated
by shRNA-NLK transfection. In contrast, NLK protein
levels were dramatically increased after transfection of the
Fig. 2 Analysis to study the correlation between NLK and Nurr1
expression in 118 PCa samples by Spearman’s rho method.
Spearman’s correlation coefficient by rank test, r = −0.597, p < 0.001
Fig. 3 NLK is involved in the suppression of Nurr1 expression in PCa cell lines. PC-3 cells were transfected with NLK-expressing or control vectors,
and LNCaP cells were transfected with a shRNA vector targeting NLK or a control nonspecific shRNA vector. a 48 h after transfection, Western blot
analysis was used to detect protein expression levels of NLK and Nurr1. b 48 h after transfection, real-time PCR was performed to detect mRNA
levels of Nurr1. c Analysis of Nurr1 promoter-luciferase activity was used to determine Nurr1 transcriptional activity. Results are plotted as means ±
SD for three independent experiments. *p < 0.05 (compared with control groups), assessed by Student’s t-test
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pcDNA3.1-NLK vector into PC-3 cells, and this upregula-
tion of NLK resulted in a significant downregulation of
Nurr1 mRNA and protein expression. These cells were
then transfected with the Nurr1 promoter luciferase con-
structs and either pcDNA3.1-NLK or shRNA-NLK. The
results confirm that Nurr1 promoter luciferase activities
vary similarly to Nurr1 mRNA and protein levels (Fig. 3c),
and strongly suggest that NLK can inhibit Nurr1 pro-
moter activity, thus leading to downregulation of Nurr1
gene expression in human PCa cells.
Knockdown of NLK in LNCaP cells upregulates Nurr1
promoter activity through both NF-κB- and CREB-binding
sites in the Nurr1 promoter region
Analysis of the promoter region of the human Nurr1
gene shows several putative cis elements, including the
upstream NF-κB-site and the downstream CREB-site
[26]. To determine the role of these binding sites in
NLK-mediated inhibition of Nurr1 transcription, we cre-
ated two mutant Nurr1 promoter luciferase constructs
(NF-κB-site mutated or CREB-site mutated), as indicated
in Fig. 4. Compared to the wild-type Nurr1 promoter
construct, mutation of either NF-κB- or CREB-binding
sites significantly impaired the upregulation of Nurr1
promoter activity induced by shRNA-NLK transfection
into LNCaP cells (Fig. 4). We also used three inhibitors,
including BAY 11–7082 (NF-κB inhibitor), KG-501
(CREB inhibitor) and ICG-001 (CREB binding protein,
CBP, inhibitor). Figure 4 shows the upregulation of
Nurr1 promoter luciferase activity induced by shRNA-
NLK under control conditions and following treatment
with BAY 11–7082, KG-501 or ICG-001. All three
Fig. 4 Knockdown of NLK in LNCap cells upregulates Nurr1 promoter activity through both NF-κB- and CREB-binding sites in the Nurr1 promoter
region. LNCaP cells were transfected with a shRNA vector targeting NLK and the three Nurr1 promoter luciferase constructs (wild-type or mutant),
as indicated. 12 h after transfecting with WT-Nurr1 promoter constructs, cells were treated with DMSO (control), BAY 11–7082 (NF-κB inhibitor),
KG-501 (CREB inhibitor) or ICG-001 (CBP inhibitor). Luciferase activity was measured 48 h after transfection. Results are plotted as means ± SD
for three independent experiments. *p < 0.05, assessed by Student’s t-test. The illustrated numbers were ratios of data in each group to that in
blank control
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inhibitors markedly inhibited Nurr1 promoter activa-
tion induced by shRNA-NLK, indicating that NF-κB-
and CREB-mediated transcriptional activation are
required for upregulation of Nurr1 gene expression by
shRNA-NLK.
CBP is a potential direct target of NLK in suppression of
NF-κB- and CREB-mediated transcription
Having demonstrated that NLK inhibits NF-κB- and
CREB-mediated transcriptional activation, we sought to
determine changes in the protein levels of p65, IκBα,
CREB and phospho-CREB in the presence of shRNA-
NLK or shRNA-control. As shown in Fig. 5a, protein
levels of p65, CREB and phospho-CREB did not change,
whereas IκBα levels decreased. We next performed
Western blotting to determine the contents of p65 in-
cluded in cytoplasmic and nuclear extracts collected
from shRNA-NLK- and control-transfected LNCaP cells,
which showed that knockdown of NLK increased the
level of p65 in nuclear extracts (Fig. 5a). Since ICG-001
(CBP inhibitor) can inhibit Nurr1 promoter activation
induced by shRNA-NLK (Fig. 4) and CBP is a nuclear
transcriptional co-activator of NF-κB and CREB, we
suspected that CBP was a target of NLK in LNCaP
cells. To test this hypothesis, dual-color fluorescence
and co-immunoprecipitation experiments were used
to investigate whether interaction occurs between the
two proteins. Immunofluorescent microscopy (Fig. 5b)
demonstrated co-localization (yellow) of NLK and
CBP in LNCaP cells. Their interaction was further
confirmed through immunoprecipitation analysis,
which detected the CBP protein in anti-NLK immu-
noprecipitates and the NLK protein in anti-CBP im-
munoprecipitates from whole cell lysates (Fig. 5c). To
determine if CBP is critical for NF-κB- and CREB-
mediated transcriptional activation of Nurr1, we used
ChIP to examine the endogenous occupancy of CBP
at the Nurr1 promoter in the presence and absence
of shRNA-NLK. As shown in Fig. 5d, compared with
controls, knockdown of NLK markedly increases the
recruitment of CBP on both the NF-κB- and CREB-
binding regions. Finally, we employed siRNA approach to
knock down CBP expression and examined if CBP was in-
volved in regulation of NLK on Nurr1 expression. As
shown in Fig. 5e, f, the regulation of NLK on Nurr1 ex-
pression was abrogated by knockdown of CBP in LNCaP
cells. Taken together, these results support the notion that
NLK directly interacts with CBP to regulate transcrip-
tional activation of Nurr1 in LNCaP cells.
Discussion
Our previous work revealed that expression of Nurr1 was
higher in PCa tissues than in benign prostate tissues, and
high levels were positively correlated with ascending
TNM classification and Gleason scores for prostate cancer
patients [16]. To date no reports have been published on
the relationship between NLK and Nurr1. In the present
study, we sought to explore this relationship through
examination of the expression levels of NLK and Nurr1 in
the same paraffin-embedded tissue samples. In contrast to
expression patterns of Nurr1, levels of NLK protein were
significantly reduced in PCa samples compared to benign
prostate tissue samples, with low NLK expression corre-
lated with progression of T and N classification and
Gleason scores. Previous studies have not found signifi-
cant differences in NLK protein expression between nor-
mal prostatic tissues and primary PCa when evaluated by
immunohistochemical staining [22], though this may be
due to small sample size. We also observed an inverse cor-
relation between the expression of NLK and Nurr1 by in-
vestigating the expression of NLK and Nurr1 in three
human prostate cell lines and eight tumors relative to
their adjacent normal fresh tissues. These data provide
direct evidence for an inverse relationship between NLK
and Nurr1 expression in PCa. We next examined the role
of NLK in the regulation of Nurr1 expression by reducing
NLK expression through RNA interference or upregulat-
ing NLK expression by transfection of NLK-expressing
plasmid vectors into PCa cells. Consistent with our previ-
ous results, up- or down-regulation of NLK expression
dramatically influenced protein and mRNA levels, and the
promoter activity of Nurr1. This suggests that NLK may
inhibit Nurr1 promoter activity, thus leading to downreg-
ulation of Nurr1 expression in human PCa cells.
DNA sequence analysis of the human Nurr1 promoter
revealed several potential regulatory regions, including
binding sites for NF-κB, CREB and Sp1 [26]. Previous
studies have demonstrated the involvement of CREB in
the transcription of Nurr1 in Hela cells, lung cancer cells
and HUVEC cells [27–29]. Other studies have also
shown that enhanced NF-κB binding of the Nurr1 pro-
moter is a important mechanism in the regulation of
Nurr1 transcription [30, 31]. To elucidate the role of
these binding sites in Nurr1 transcription, we mutated
NF-κB- and CREB-binding sites of Nurr1 promoter lu-
ciferase constructs and used three specific inhibitors of
these proteins. Our results suggested that upregulation
of Nurr1 gene expression induced by shRNA-NLK de-
pends on NF-κB- and CREB-binding sites for transcrip-
tional activation in LNCaP cells.
NF-κB is a nuclear transcription factor that binds to
NF-κB response elements within target genes [32, 33].
Under resting conditions, NF-κB is maintained as a
latent complex in the cytoplasm by the inhibitory IκB
proteins [34]. In the canonical activation pathway,
IκBα is phosphorylated by the IκB kinase (IKK) complex.
Phosphorylation of IκBα on serines 32 and 36 triggers its
ubiquitination and proteasome-dependent degradation,
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thus permitting the translocation of bound NF-κB dimers
to the nucleus and gene expression activation [35]. In the
present study, we found that levels of IκBα were reduced,
and that the nuclear:cytoplasmic ratio of p65 protein was
increased following induction by shRNA-NLK. A previous
study showed that NLK competes with TAK1 to bind
IKKβ, leading to inhibition of activation by the IKKβ
phosphorylation and IκBα degradation [36]. Presumably, a
similar mechanism may be responsible for nuclear trans-
location of p65 by NLK knockdown in LNCaP cells.
Fig. 5 CBP is a potential direct target of NLK in suppression of the NF-κB- and CREB-mediated transcription in LNCaP cells. a 48 h after transfection,
Western blot analysis was used to detect protein levels of p65, IκBα, CREB and phosphorylated CREB (Ser133). For analysis of the subcellular distribution
of p65, LNCaP cells were fractionated into cytoplasmic and nuclear fractions. b NLK and CBP are co-localized in the LNCaP cells. Cells were subjected
to immunofluorescence with anti-NLK antibody followed by FITC-conjugated antibody (green) and anti-CBP antibody followed by Cy3-conjugated
antibody (red). c Interaction of NLK with CBP in LNCaP whole cell extract. LNCaP cells were lysed and used for Co-IP assays with anti-NLK, anti-CBP or
normal IgG antibody. d ChIP analysis of CBP occupancy of the Nurr1 promoter in LNCaP cells transfected with shRNA-control or shRNA-NLK. e 48 h
after transfection, Western blot analysis was used to detect protein expression levels of CBP, NLK and Nurr1. f: 48 h after transfection, real-time PCR was
performed to detect mRNA levels of Nurr1. Data are means ± SD for three independent experiments. *p < 0.05, assessed by Student’s t-test
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However, we found this nuclear translocation is not strong
(Fig. 5a). Moreover, NF-κB-mediated transcriptional acti-
vation requires the help of its coactivators in the nucleus
[37], so the NLK in nucleus may be more important than
those in cytoplasm in the regulation of Nurr1 gene
transcription.
CREB was one of the first transcription factors purified
by DNA affinity chromatography using the cyclic AMP
binding element (CRE) of the somatostatin gene [38].
Activation of CREB is mediated by phosphorylation at
its serine 133 residue, which promotes the association of
CREB with CBP/p300, leading to transcriptional activation
of its target genes through histone modification and re-
cruitment of an active transcription complex [39, 40]. Our
results indicate that knockdown of NLK does not affect
the levels of expression and phosphorylation of the CREB
protein, suggesting that CREB itself is not a direct target
of NLK that results in its transcriptional suppression.
We found that the CBP inhibitor ICG-001 markedly
inhibited NLK knockdown- induced Nurr1 promoter ac-
tivation, suggesting that CBP may participate in NLK-
mediated repression of Nurr1 promoter activity. CBP
and its homologue p300 possess intrinsic histone
acetyltransferase (HAT) activity, and are also transcrip-
tional co-activators of various sequence-specific tran-
scription factors such as NF-κB, AP-1, Smad and p53
[41–44]. CBP/p300 can enhance transcriptional activity
either through their protein acetyltransferase activity or
by acting as scaffold proteins to recruit other coregula-
tors or components of the basal transcription machinery
[45–47]. CBP/p300 functionally interact with a region of
the NF-κB p65 subunit containing the transcriptional acti-
vation domain and potentiates p65-activated transcription
[48]. Thus, recruitment of CBP/p300 to transcription fac-
tors is required for NF-κB- and CREB-mediated transcrip-
tional activation. A previous study indicated that NLK
may regulate protein-protein interactions mediated by
phosphorylation of the C-terminal region of CBP and sup-
press its function. NLK carries out this function to repress
CBP through its kinase-dependent activity [23]. Our study
demonstrated that NLK and CBP physically interact, sug-
gesting that NLK may inhibit NF-κB- and CREB-mediated
transcriptional activation through downregulation of
NF-κB-CBP/p300 and CREB-CBP/p300 complexes. ChIP
analysis further demonstrated that NLK knockdown pro-
motes recruitment of CBP to both NF-κB- and CREB-
Fig. 6 Schematic representation of the proposed signaling pathways for NLK-inhibited Nurr1 expression in PCa cells
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binding regions of the Nurr1 promoter. Taken together,
these evidences suggest that CBP is likely to be an import-
ant direct target of NLK in the regulation of Nurr1 expres-
sion in prostate cancer.
Although the activation of AR participated in the acti-
vation of NF-κB signaling pathway [49], it is not the only
cause for the activation of this pathway [50, 51]. In
addition, no androgen-treated cells were used in the
present study. Hence, we speculate that although we
used two cell lines with different characteristics of an-
drogen independency, the results will not be substan-
tially affected. The aim of this study was to elucidate the
mechanisms underlying the regulation of transcription
of Nurr1 by NLK. The association between androgen
and Nurr1 could not be determined and will be investi-
gated in our future studies. We speculate that regulation
of expression of Nurr1 in prostate cancer could be
androgen-independent or partially-dependent.
Conclusions
NLK is a transcriptional repressor of Nurr1 expression
in human PCa. Reduced expression of NLK may attenu-
ate inhibition of CBP function as co-activator of NF-κB
and CREB, thus promoting transcriptional activation of
Nurr1 gene (Fig. 6). Further studies are needed to delin-
eate the effect and precise mechanisms of the NLK/Nurr1
signaling pathway in PCa development and progression,
and also to demonstrate the value of this pathway as a
therapeutic target.
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